SOLV vs. RMD, WST, BAX, PODD, SWAV, TFX, GMED, PEN, GKOS, and MMSI
Should you be buying Solventum stock or one of its competitors? The main competitors of Solventum include ResMed (RMD), West Pharmaceutical Services (WST), Baxter International (BAX), Insulet (PODD), Shockwave Medical (SWAV), Teleflex (TFX), Globus Medical (GMED), Penumbra (PEN), Glaukos (GKOS), and Merit Medical Systems (MMSI). These companies are all part of the "surgical & medical instruments" industry.
Solventum (NYSE:SOLV) and ResMed (NYSE:RMD) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, community ranking, dividends and analyst recommendations.
55.0% of ResMed shares are held by institutional investors. 1.2% of ResMed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
ResMed has a net margin of 20.91% compared to Solventum's net margin of 0.00%. ResMed's return on equity of 24.43% beat Solventum's return on equity.
Solventum presently has a consensus target price of $69.67, suggesting a potential upside of 16.38%. ResMed has a consensus target price of $202.80, suggesting a potential downside of 2.11%. Given Solventum's higher possible upside, equities research analysts clearly believe Solventum is more favorable than ResMed.
ResMed received 415 more outperform votes than Solventum when rated by MarketBeat users. Likewise, 52.93% of users gave ResMed an outperform vote while only 0.00% of users gave Solventum an outperform vote.
In the previous week, ResMed had 5 more articles in the media than Solventum. MarketBeat recorded 5 mentions for ResMed and 0 mentions for Solventum. ResMed's average media sentiment score of 0.88 beat Solventum's score of 0.00 indicating that ResMed is being referred to more favorably in the news media.
ResMed has higher revenue and earnings than Solventum.
Summary
ResMed beats Solventum on 12 of the 13 factors compared between the two stocks.
Get Solventum News Delivered to You Automatically
Sign up to receive the latest news and ratings for SOLV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SOLV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Solventum Competitors List
Related Companies and Tools
